Barclays analyst Stephanie Davis lowered the firm’s price target on Walgreens Boots Alliance to $7 from $11 and keeps an Underweight rating on the shares. The firm updated its model to reflect lower U.S. retail pharmacy revenues and margins for FY25 amid continued macro challenges, noting that its FY25 revenue and EPS estimates were lowered to $145.1B and $1.74.from $146.9B and $2.58, respectively.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WBA:
- Supermicro up 3% after selected to join Nasdaq-100 Index
- Class Action Filed Against Walgreens Boots Alliance, Inc. (WBA) Seeking Recovery for Investors – Contact Levi & Korsinsky LLP
- Walgreens Announces Major Executive Appointment
- Walgreen Boots call volume above normal and directionally bullish
- Walgreens Boots Alliance price target lowered to $12 from $17 at UBS